Recently, immunotherapies, mainly immune checkpoint inhibitors of the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway, have emerged as an encouraging antitumour strategy for HCC [1,2]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.